Calliditas Therapeutics AB (publ) (CALT)
Calliditas Therapeutics AB (publ)
Kungsbron 1, D5
Stockholm 111 22
Sweden
46 84 11 30 05
https://www.calliditas.se
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 217
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Ms. Renee Aguiar-Lucander | Chief Executive Officer | 11.72M | N/D | 1962 |
| Mr. Fredrik Johansson | Chief Financial Officer | N/D | N/D | 1977 |
| Lars Stubberud | Head of Technical Operations | N/D | N/D | 1964 |
| Ms. Asa Hillsten | Head of IR & Sustainability | N/D | N/D | 1975 |
| Mr. Brian Gorman | Group General Counsel | N/D | N/D | 1976 |
| Ms. Sandra Frithiof | Head of Human Resources | N/D | N/D | 1975 |
| Ms. Ann-Kristin Myde BSc | Head of Clinical Development & VP of Project Management | N/D | N/D | 1955 |
| Dr. Richard S. Philipson M.D. | Chief Medical Officer | N/D | N/D | 1964 |
| Ms. Teona Johnson | Head of US Marketing | N/D | N/D | N/D |
| Mr. David Ferraro | Head of US Sales | N/D | N/D | N/D |
Descripción
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.
Gestión corporativa
La calificación ISS Governance QuickScore de Calliditas Therapeutics AB (publ) a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
